Thyroid Drug Recall Most Serious; GLP-1s and Vitamin Deficiency; New T1D Guidelines

The FDA designated Vitruvias Therapeutics’ recall of a lot of 30-mg levothyroxine-liothyronine tablets (Thyroid Tablets) as Class I, its most serious classification. (USA Today)

At least six major U.S. hospitals have shut down their gender transition services and agreed to pay fines to close out investigations by the Justice Department; some have even offered free care to former patients who want to detransition. (New York Times)

Roche halted development of emugrobart, an investigational muscle-building drug designed to be paired with GLP-1/GIP receptor agonists, after a disappointing interim analysis from a phase II study.

A preprint published at Preprints.org suggested that a patient’s weight trajectory in the years leading up to initiation of a GLP-1 drug may predict whether they become a “super responder.”

A study showed that nearly 17% of adolescents taking a GLP-1 drug were diagnosed with at least one nutritional deficiency — most frequently vitamin D deficiency — within the first year of initiation. (Childhood Obesity)

Viking Therapeutics said trial participants taking its investigational dual-acting obesity drug maintained virtually all weight loss after switching from a weekly shot to less frequent dosing in a phase II trial.

Eli Lilly reported that tirzepatide (Zepbound) yielded greater weight loss than semaglutide (Wegovy HD) in an indirect comparison of trials presented at the European Association for the Study of Diabetes (EASD) annual meeting.

And in an indirect comparison of adult type 2 diabetes trials, Lilly said its oral GLP-1 drug orforglipron (Foundayo) was associated with greater weight loss and a greater HbA1c reduction versus oral semaglutide (Rybelsus).

Meanwhile, rival Novo Nordisk said adults with type 2 diabetes on semaglutide (Ozempic) who doubled their dose had a lower risk of major adverse cardiovascular events compared with those switching to tirzepatide (Mounjaro).

A growing number of people are taking GLP-1 drugs without any clear medical reason to do so, researchers found. (New York Times)

The American Diabetes Association and EASD issued updated joint consensus guidelines for managing type 1 diabetes (T1D) in adults. (Diabetes Care)

In a phase IIb/III trial, the novel tri-specific agonist remigromig demonstrated noninferiority to standard ranibizumab (Lucentis) on vision outcomes for adults with diabetic macular edema, Merck announced.

The world’s first mandatory healthy checkout ordinance in Berkeley, California, was associated with decreased soda sales but not candy sales, a quasi-experimental study found. (Lancet Public Health)

Real-world data indicated that baseline morning salivary cortisone performed at least as well as serum cortisol when screening for adrenal insufficiency. (Journal of Clinical Endocrinology & Metabolism)